**Core Concept**
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a genetic disorder that affects the enzyme responsible for protecting red blood cells from oxidative damage. Patients with G6PD deficiency are at risk of hemolysis when exposed to certain drugs that generate oxidative stress.

**Why the Correct Answer is Right**
The correct answer is a drug that induces oxidative stress, leading to hemolysis in patients with G6PD deficiency. This is because G6PD is crucial for maintaining the integrity of red blood cells by preventing the accumulation of reactive oxygen species (ROS). Drugs that increase ROS production can overwhelm the protective mechanisms of G6PD, leading to hemolysis. The drug in question is primaquine, a well-known oxidizing agent that can cause hemolysis in patients with G6PD deficiency.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because, although it may have some side effects, it is not commonly associated with hemolysis in patients with G6PD deficiency.
* **Option B:** This option is incorrect because it is not typically considered a risk factor for hemolysis in G6PD deficiency.
* **Option D:** This option is incorrect because it is not known to cause oxidative stress or hemolysis in patients with G6PD deficiency.

**Clinical Pearl / High-Yield Fact**
When prescribing medications to patients with G6PD deficiency, it's essential to consider the potential risk of hemolysis and choose alternative medications when possible. Primaquine is a classic example of a medication that should be avoided in patients with G6PD deficiency.

**Correct Answer: C. Primaquine**